IRIS
BUTTINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.263
AS - Asia 5.997
EU - Europa 4.200
SA - Sud America 837
Continente sconosciuto - Info sul continente non disponibili 303
AF - Africa 267
OC - Oceania 36
Totale 18.903
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.067
SG - Singapore 2.104
CN - Cina 1.557
IT - Italia 1.033
VN - Vietnam 903
IE - Irlanda 729
BR - Brasile 640
SE - Svezia 487
HK - Hong Kong 455
FI - Finlandia 378
DE - Germania 362
FR - Francia 307
BD - Bangladesh 267
NL - Olanda 225
ZA - Sudafrica 178
TR - Turchia 165
GB - Regno Unito 145
UA - Ucraina 143
IN - India 119
CA - Canada 107
RU - Federazione Russa 98
AR - Argentina 85
KR - Corea 80
AT - Austria 76
ES - Italia 51
ID - Indonesia 50
MX - Messico 49
JP - Giappone 45
IQ - Iraq 43
TW - Taiwan 34
PL - Polonia 33
BE - Belgio 32
AU - Australia 28
CO - Colombia 28
PK - Pakistan 27
EC - Ecuador 25
MA - Marocco 22
PY - Paraguay 21
PH - Filippine 20
CZ - Repubblica Ceca 19
UZ - Uzbekistan 17
MY - Malesia 15
TH - Thailandia 15
CI - Costa d'Avorio 13
PT - Portogallo 13
RS - Serbia 12
VE - Venezuela 12
CL - Cile 10
IR - Iran 10
KE - Kenya 10
ET - Etiopia 9
JM - Giamaica 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
AZ - Azerbaigian 8
JO - Giordania 8
KZ - Kazakistan 8
LT - Lituania 8
NZ - Nuova Zelanda 8
BO - Bolivia 7
CR - Costa Rica 7
DZ - Algeria 7
EG - Egitto 6
HU - Ungheria 6
RO - Romania 6
TN - Tunisia 6
AL - Albania 5
EU - Europa 5
GT - Guatemala 5
HR - Croazia 5
PE - Perù 5
QA - Qatar 5
BH - Bahrain 4
CH - Svizzera 4
LB - Libano 4
PA - Panama 4
SN - Senegal 4
EE - Estonia 3
NO - Norvegia 3
NP - Nepal 3
PS - Palestinian Territory 3
SC - Seychelles 3
UY - Uruguay 3
AO - Angola 2
BY - Bielorussia 2
DK - Danimarca 2
GA - Gabon 2
GR - Grecia 2
HN - Honduras 2
IL - Israele 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
OM - Oman 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AG - Antigua e Barbuda 1
AM - Armenia 1
BB - Barbados 1
Totale 18.582
Salva come PNG Salva come JPEG
Città #
Singapore 1.071
Ashburn 915
Dublin 721
San Jose 711
Chandler 627
Santa Clara 435
Hong Kong 434
Dallas 419
Beijing 375
Council Bluffs 290
Ho Chi Minh City 263
Parma 255
Dearborn 220
Hanoi 204
Boardman 201
Johannesburg 167
Jacksonville 164
Ann Arbor 150
Nanjing 147
Los Angeles 146
Lauterbourg 131
New York 124
Princeton 116
Shanghai 116
Izmir 108
Munich 107
Milan 102
Hefei 97
Wilmington 92
Columbus 71
Helsinki 66
Seoul 66
Moscow 63
Vienna 56
Chicago 55
São Paulo 53
Seattle 50
Buffalo 49
Rome 48
Bologna 46
Bremen 46
Da Nang 44
Haiphong 44
Shenyang 42
San Mateo 41
London 38
Nanchang 38
Turku 38
The Dalles 36
Brooklyn 34
Orem 34
Atlanta 33
Changsha 33
Groningen 33
Toronto 33
Guangzhou 32
Kunming 32
Woodbridge 31
Frankfurt am Main 30
Hebei 30
Houston 30
Jakarta 30
Jiaxing 30
Reggio Emilia 29
Des Moines 28
Tianjin 28
Brussels 26
Warsaw 26
Jinan 25
Marseille 24
Montreal 24
San Francisco 24
Tokyo 24
Falls Church 23
Stockholm 23
Amsterdam 22
Chennai 22
Sydney 22
Phoenix 21
Ardea 20
Mexico City 20
Ferrara 18
Hillsboro 17
Istanbul 17
Norwalk 17
Pune 16
Rio de Janeiro 16
Fremont 15
Hải Dương 15
Nuremberg 15
Poggio Renatico 15
Denver 14
Naples 14
Abidjan 13
Grafing 13
Kocaeli 13
Manchester 13
Porto Alegre 13
Belo Horizonte 12
Bắc Ninh 12
Totale 11.052
Salva come PNG Salva come JPEG
Nome #
Chimeral agglomerates of microparticles for the administration of caffeine nasal powders 399
Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays 351
Curcumin and Quercetin-Loaded Lipid Nanocarriers: Development of Omega-3 Mucoadhesive Nanoemulsions for Intranasal Administration 267
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 247
Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa 235
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro 230
Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease 228
Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens 214
The Impact of Possible Misuses Conditions on in Vitro Performance of NEXThaler in Comparison with Ellipta Inhaler 209
Inhalable microparticles embedding calcium phosphate nanoparticles for heart targeting: The formulation experimental design 206
Opportunity and challenges of nasal powders: Drug formulation and delivery 205
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant 198
Nebulizers effectiveness on pulmonary delivery of alpha-1 antitrypsin 190
CHIMERAL AGGLOMERATES OF MICRONIZED POWDER FOR NASAL ADMINISTRATION OF ANALGESIC DRUG 181
Agglomerates of Morphine Microcrystals for Nasal or Buccal Administration 175
Solid-state characterization of tobramycin powders for inhalation 172
Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients 172
Therapeutic effect of cyclosporine A-loading TPGS micelles on a mouse model of LPS-induced neuroinflammation 171
Consequences of not-shaking and shake-fire delays on the emitted dose of some commercial solution and suspension pressurized metered dose inhalers 170
Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation 169
Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction 167
A dry powder formulation for peripheral lung delivery and absorption of an anti-SARS-CoV-2 ACE2 decoy polypeptide 160
Nasal inhalation of antiviral microparticulate powders to target early infection of upper airways 159
Aerosolization performance of jet nebulizers and biopharmaceutical aspects 158
Polysaccharides: New Frontiers for Nasal Administration of Medicines 157
A Clinical Study of a Methacholine Dry Powder for the Bronchial Challenge Test 155
Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages 155
Respicell(TM): An innovative dissolution apparatus for inhaled products 154
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2 154
Design and Characterization of Maltoheptaose-b-Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen 153
"Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs 151
Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers 151
Nebulized coenzyme Q10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy 150
Dose administration manoeuvres and patient care in tobramycin dry powder inhalation therapy 150
A DRUG POWDER FOR INHALATION ADMINISTRATION AND PROCESS THEREOF 149
Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections 149
High shear mixing of lactose and salmeterol xinafoate dry powder blends: biopharmaceutic and aerodynamic performances 148
Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery 147
Crystalline Microparticles of a Beta-Agonist Coated with a Fatty Acid 146
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting 145
Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation 144
Chimeral agglomerates of microparticles for nasal administration of analgesic drug powders 142
Crystallization of stable doped mannitol polymorphs and in vitro assessment of their safety as carriers for lung delivery 141
Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure 140
The role of airways microbiota on local and systemic diseases: a rationale for probiotics delivery to the respiratory tract 140
Caratterizzazione e modellazione del comportamento meccanicodella valvola di un pMDI. 140
Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency 139
Nasal delivery as a strategy for the prevention and treatment of COVID-19 136
The use of multilayer poly(vinyl alcohol) adsorption to fabricate drug rich inhalable microparticles. 134
Mannitol polymorphs as carrier in dpis formulations: Isolation characterization and performance 134
No-shaking and shake-fire delays affect respirable dose for suspension but not solution pMDIs 132
Dry powder inhalation technology for heart targeting applied to calcium phosphate nanoparticles loaded with active substances 130
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 130
Respirable amikacin dry powders for inhalation by a Quality bu Design procedure 129
Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats 128
Characterisation of Particles Emitted from Two Formulations of Beclomethasone Dipropionate Solution Metered Dose Inhalers 128
Dry Coating Technique for Inhalation Powders 127
Compositions in powder form made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation 126
No-shaking and shake-fire delays affect respirable dose for suspension but not solution pMDIs (vol 631, 122478, 2023) 125
Compositions in powder from made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation 125
Evaluation of the Physico-mechanical Properties and Electrostatic Charging Behavior of Different Capsule Types for Inhalation Under Distinct Environmental Conditions 125
Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction 125
Sodium Hyaluronate Microparticles for Pulmonary Delivery of Anti-mycobacterial Drugs 123
Back to Basics: The development of a simple, homogenous, two-component dry powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers. 123
Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations 123
Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect 122
Particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone having improved adhesion properties for powder formulations for inhalation 122
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients 122
Aerodynamic assessment for inhalation products: fundamentals and current pharmacopoeial methods 121
Performance of Different Nebulizers in the Aerosolization of Colistimethate Sodium 121
The role of lipophilic adjuvant to produce high respirable tobramicin powders for inhalation 121
Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler® in Comparison with Diskus® and Turbohaler® Dry Powder Inhalers 121
Layered lipid microcapsules for mesalazine delayed-release in children 118
Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptake 118
LACTOBACILLI INHALATION POWDER FOR THE REDUCTION OF LUNG INFLAMMATION IN non-CF BRONCHIECTASIS DISEASE 116
Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam 116
Formulation Strategies for Antitubercular Drugs by Inhalation 116
Lipid-core nanocapsules are an alternative to the pulmonary delivery and to increase the stability of statins 116
The development of amikacin dry powder for pulmonary administration 115
100 years of drug delivery to the lungs 115
AEROSOLIZED SULFATED HYALURONAN DERIVATIVES PROLONG THE SURVIVAL OF K18 ACE2 MICE INFECTED WITH A LETHAL DOSE OF SARS-COV-2 114
Ex vivo permeation of tamoxifen and its 4-OH metabolite through rat intestine from lecithin/chitosan nanoparticles 114
Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the in Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler 114
Particles and powders: Tools of innovation for non-invasive drug administration 114
High Respirable Insulin Dry Powder for Pulmonary Administration 113
Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation 113
Inhalable spray-dried chondroitin sulphate microparticles: Effect of different solvents on particle properties and drug activity 112
POLVERI NASALI DI MORFINA PER UNA RAPIDA ANALGESIA 112
Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis 112
Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-D-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy 111
Resistant tuberculosis: The latest advancements of second-line antibiotic inhalation products 111
The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers 109
Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents 109
The impact of lipid corona on rifampicin intramacrophagic transport using inhaled solid lipid nanoparticles surface-decorated with a mannosylated surfactant 109
Inhalable Microparticles Embedding Biocompatible Magnetic Iron-Doped Hydroxyapatite Nanoparticles 108
The Influence of Energy Input During Dry Powder Blending on Dynamic Flow Properties, Powder Aerosolization and Dissolution of Dry Powders for Inhalation 107
Nanostructures for overcoming the pulmonary barrier: drug delivery strategies 106
NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION 105
INHALATION DRUG DELIVERY Techniques and Products 105
Influence of Sodium Stearate on Amikacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis Patients with Pseudomonas Aeruginosa Lung Infections 105
Totale 14.719
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.676
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022579 0 7 14 32 37 36 64 58 38 39 19 235
2022/20232.342 244 218 132 186 175 254 29 166 774 31 97 36
2023/20241.220 56 79 24 60 93 205 222 89 34 87 111 160
2024/20253.505 88 184 223 292 305 386 195 150 385 347 295 655
2025/20267.619 611 647 949 662 1.013 404 825 231 992 557 448 280
2026/2027999 540 459 0 0 0 0 0 0 0 0 0 0
Totale 18.903